Treats overactive bladder with symptoms of urge urinary incontinence, urgency, and…. ANDA 78503, held by Osmotica Pharm US. Oxybutynin Chloride.
As of Nov 16, 2026, ANDA 78503 (Oxybutynin Chloride), held by Osmotica Pharm US, was first approved by FDA on Feb 4, 2009, with 7 approved supplements and 0 published complete response letters.
Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 4, 2009 | Original application | Approved |
| Oxybutynin Chloride5MG · tablet, extended release;oral | Oxybutynin Chloride | Rx |
| Oxybutynin Chloride10MG · tablet, extended release;oral | Oxybutynin Chloride | Rx |
| Oxybutynin Chloride15MG · tablet, extended release;oral | Oxybutynin Chloride | Rx |
| Sep 9, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Sep 9, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 4, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 4, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 30, 2013 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 30, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 7, 2010 | Supplement 2Labeling | Approved | None posted |
| Feb 4, 2009 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters